JP2011527331A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011527331A5 JP2011527331A5 JP2011517245A JP2011517245A JP2011527331A5 JP 2011527331 A5 JP2011527331 A5 JP 2011527331A5 JP 2011517245 A JP2011517245 A JP 2011517245A JP 2011517245 A JP2011517245 A JP 2011517245A JP 2011527331 A5 JP2011527331 A5 JP 2011527331A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound
- compound according
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000003839 salts Chemical class 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 26
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- -1 3-azetidinyl Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- VUCWMAJEUOWLEY-UHFFFAOYSA-N 1-$l^{1}-azanylpiperidine Chemical compound [N]N1CCCCC1 VUCWMAJEUOWLEY-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 230000036186 satiety Effects 0.000 claims 1
- 235000019627 satiety Nutrition 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0812622.9 | 2008-07-10 | ||
| GB0812646A GB0812646D0 (en) | 2008-07-10 | 2008-07-10 | Compounds |
| GB0812646.8 | 2008-07-10 | ||
| GB0812622A GB0812622D0 (en) | 2008-07-10 | 2008-07-10 | Compounds |
| GB0902391.2 | 2009-02-13 | ||
| GB0902391A GB0902391D0 (en) | 2009-02-13 | 2009-02-13 | Compounds |
| PCT/GB2009/050825 WO2010004343A1 (en) | 2008-07-10 | 2009-07-10 | Piperidinyl gpcr agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011527331A JP2011527331A (ja) | 2011-10-27 |
| JP2011527331A5 true JP2011527331A5 (enExample) | 2012-08-16 |
Family
ID=41070447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011517245A Withdrawn JP2011527331A (ja) | 2008-07-10 | 2009-07-10 | ピペリジニルｇｐｃｒ作動薬 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20110269734A1 (enExample) |
| EP (1) | EP2321297A1 (enExample) |
| JP (1) | JP2011527331A (enExample) |
| KR (1) | KR20110036609A (enExample) |
| CN (1) | CN102083813A (enExample) |
| AU (1) | AU2009269772A1 (enExample) |
| CA (1) | CA2728042A1 (enExample) |
| CL (1) | CL2011000051A1 (enExample) |
| EA (1) | EA201170151A1 (enExample) |
| IL (1) | IL209978A0 (enExample) |
| MA (1) | MA32467B1 (enExample) |
| MX (1) | MX2011000060A (enExample) |
| PE (1) | PE20110329A1 (enExample) |
| WO (1) | WO2010004343A1 (enExample) |
| ZA (1) | ZA201008955B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011518146A (ja) * | 2008-04-17 | 2011-06-23 | ファイザー・インク | Ｆａａｈ阻害剤として有用な４−［３−（アリールオキシ）ベンジリデン］−３−メチルピペリジンアリールカルボキサミド化合物 |
| GB0904285D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB0904284D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB0904287D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| RS56654B8 (sr) | 2009-05-13 | 2021-06-30 | Gilead Pharmasset Llc | Antiviralna jedinjenja |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| JP2012530758A (ja) | 2009-06-24 | 2012-12-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規化合物、医薬組成物及びそれに関する方法 |
| NZ596445A (en) | 2009-06-24 | 2013-04-26 | Boehringer Ingelheim Int | New compounds, pharmaceutical composition and methods relating thereto |
| EP2547339A1 (en) | 2010-03-18 | 2013-01-23 | Boehringer Ingelheim International GmbH | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
| GB201006167D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB201006166D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| TW201209054A (en) | 2010-05-28 | 2012-03-01 | Prosidion Ltd | Novel compounds |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| GB201114389D0 (en) | 2011-08-22 | 2011-10-05 | Prosidion Ltd | Novel compounds |
| WO2012066077A1 (en) | 2010-11-18 | 2012-05-24 | Prosidion Limited | 1,4 di substituted pyrrolidine - 3 - yl -amine derivatives and their use for the treatment of metabolic disorders |
| EP2693882B1 (en) | 2011-04-08 | 2017-06-28 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
| CA2838079A1 (en) | 2011-06-16 | 2012-12-20 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| SI2709613T2 (sl) | 2011-09-16 | 2020-12-31 | Gilead Pharmasset LLC c/o Gilead Sciences, Inc. | Postopki za zdravljenje HCV |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760855B1 (en) | 2011-09-30 | 2017-03-15 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds as well as their use in treating type-2 diabetes |
| US9018200B2 (en) | 2011-10-24 | 2015-04-28 | Merck Sharp & Dohme Corp. | Substituted piperidinyl compounds useful as GPR119 agonists |
| US9018224B2 (en) | 2011-11-15 | 2015-04-28 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds useful as GPR119 agonists |
| NZ729172A (en) | 2013-01-31 | 2018-06-29 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| JP2016529293A (ja) | 2013-08-27 | 2016-09-23 | ギリアド ファーマセット エルエルシー | ２つの抗ウイルス化合物の組合せ製剤 |
| WO2018068295A1 (en) * | 2016-10-14 | 2018-04-19 | Merck Sharp & Dohme Corp. | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE |
| BR112022006546A2 (pt) * | 2019-10-07 | 2022-08-30 | Kallyope Inc | Agonistas de gpr119 |
| CA3173731A1 (en) | 2020-02-28 | 2021-09-02 | Kallyope, Inc. | Gpr40 agonists |
| CA3219397A1 (en) | 2021-05-21 | 2022-11-24 | Gilead Sciences, Inc. | Tetracyclic compounds for the treatment of zika virus infection |
| JP7725617B2 (ja) | 2021-05-21 | 2025-08-19 | ギリアード サイエンシーズ， インコーポレイテッド | ジカウイルス阻害剤としての五環式誘導体 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ564759A (en) * | 2005-06-30 | 2011-08-26 | Prosidion Ltd | GPCR agonists |
-
2009
- 2009-07-10 EA EA201170151A patent/EA201170151A1/ru unknown
- 2009-07-10 PE PE2011000013A patent/PE20110329A1/es not_active Application Discontinuation
- 2009-07-10 CN CN2009801263533A patent/CN102083813A/zh active Pending
- 2009-07-10 EP EP09785303A patent/EP2321297A1/en not_active Withdrawn
- 2009-07-10 CA CA2728042A patent/CA2728042A1/en not_active Abandoned
- 2009-07-10 JP JP2011517245A patent/JP2011527331A/ja not_active Withdrawn
- 2009-07-10 MX MX2011000060A patent/MX2011000060A/es not_active Application Discontinuation
- 2009-07-10 KR KR1020117002904A patent/KR20110036609A/ko not_active Withdrawn
- 2009-07-10 WO PCT/GB2009/050825 patent/WO2010004343A1/en not_active Ceased
- 2009-07-10 AU AU2009269772A patent/AU2009269772A1/en not_active Abandoned
- 2009-07-10 US US13/003,546 patent/US20110269734A1/en not_active Abandoned
-
2010
- 2010-12-13 ZA ZA2010/08955A patent/ZA201008955B/en unknown
- 2010-12-13 IL IL209978A patent/IL209978A0/en unknown
-
2011
- 2011-01-10 CL CL2011000051A patent/CL2011000051A1/es unknown
- 2011-01-10 MA MA33508A patent/MA32467B1/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011527332A5 (enExample) | ||
| JP2011527333A5 (enExample) | ||
| JP2010514831A5 (enExample) | ||
| JP2010514829A5 (enExample) | ||
| JP2011527334A5 (enExample) | ||
| JP2009534468A5 (enExample) | ||
| JP2010514832A5 (enExample) | ||
| JP2011528658A5 (enExample) | ||
| JP2013542261A5 (enExample) | ||
| EP1857457A3 (en) | Benzimidazole derivative and its use as AII receptor antagonist | |
| TW200728307A (en) | Novel spirochromanone derivatives | |
| JP2011529054A5 (enExample) | ||
| HRP20090235A2 (hr) | Karbonilirani (aza) cikloheksani kao ligandi dopaminskog receptora d<sub>3</sub> | |
| GEP20135744B (en) | Quinuclidine carbonate derivatives and medicinal compositions containing the same | |
| JP2011527335A5 (enExample) | ||
| NO20072371L (no) | Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister | |
| MX2010007375A (es) | Nuevos derivados de lupano. | |
| UA92670C2 (ru) | Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе | |
| WO2007146758A3 (en) | Novel mch receptor antagonists | |
| MX2010007374A (es) | Nuevos derivados de c-21-ceto lupano, preparacion y uso de los mismos. | |
| DE602004011394D1 (en) | Thiazolderivate | |
| JP2014507477A5 (enExample) | ||
| MX2011013648A (es) | Nuevos compuestos, composiciones farmaceuticas y metodos relacionados con ellos. | |
| JP2012507535A5 (enExample) | ||
| MX2009012125A (es) | Compuestos terapeuticos. |